Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers

The expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. Thus, there is a need to develop other biomarkers, which can be used to accurately select responsive patients for targeted therapies. The HER dimerization status may be more important than H...

Descripción completa

Detalles Bibliográficos
Autores principales: Waterhouse, Benjamin R., Gijsen, Merel, Barber, Paul R., Tullis, Iain D.C., Vojnovic, Borivoj, Kong, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Methodological Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248220/
https://www.ncbi.nlm.nih.gov/pubmed/21908901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248220/
https://www.ncbi.nlm.nih.gov/pubmed/21908901

Ejemplares similares